Fed. Circ. Affirms Patent Extension For Levaquin
Daiichi's patent on the drug, known generically as levofloxacin, was properly granted the statutory term extension, a three-judge panel in the U.S. Court of Appeals for the Federal Circuit ruled Monday.
Levofloxacin is a different drug product from the related “racemate” drug ofloxacin, and was subject to regulatory approval before it...
To view the full article, register now.